The potential benefit of angiotensin II-receptor antagonism is not limited ... afforded to these agents by their nonpeptide chemical structure. Although ARBs have some structural and ...

High-dose angiotensin-converting-enzyme inhibitors, however, are at least as effective as high-dose angiotensin blockers and less expensive. Angiotensin-converting-enzyme inhibition is thus the ...

Currently, there is evidence supporting the use of either an angiotensin receptor blocker or an angiotensin-converting enzyme inhibitor in the primary-prevention context. However, in the secondary ...

SARS-CoV-2, the virus responsible for COVID-19, infects cells by binding its spike protein to angiotensin-converting enzyme 2 ...

The dual-action agent LCZ696 blocks the angiotensin II receptor (via a valsartan moiety) and inhibits neprilysin (via an AHU377 moiety). In a phase II trial, this drug “demonstrated superior ...